Page 18 - 2018_11-Haematologica-web

1758
Editorials
Older adults with acute myeloid leukemia treated with intensive chemotherapy: “old” prognostic algorithms may not apply
Richard M. Stone and Coleman Lindsley
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
E-mail: rstone@partners.org doi:10.3324/haematol.2018.201848
The notion that older adults with acute myeloid leukemia (AML) represent a major therapeutic chal- lenge due to host biological factors and intrinsic dis- ease features leading to poor outcomes is accepted by con- sensus. Older adults have diminished stem cell reserve, more frequent comorbid medical conditions, and decreased ability to excrete chemotherapy compared to younger patients, in part leading to a relatively increased rate of mor- tality from induction treatment.1 Moreover, AML that arises in the older population can exhibit features of intrinsic chemo-resistance exemplified by a higher expression of proteins that extrude chemotherapy, a higher proportion of adverse cytogenetic abnormalities,2 and a higher frequency of gene mutations associated with antecedent myeloid dis- ease, which are, in turn, associated with an elevated rate of disease resistance.3 Based on this unfavorable balance of response and toxicity, many believe that older patients, especially those over the age of 75, should as a whole be treated with less intensive therapies: usually a hypomethy- lating agent (azacytidine or decitabine) in the USA or low- dose cytarabine.4 In counterpoint, a population-based study from Sweden suggested that older adults may benefit from intensive treatment, while others have shown that the genetic characteristics5 of AML in older patients may dis- criminate subgroups with distinct clinical responses to intensive therapy.3 For example, patients with de novo AML genetic alterations have a higher likelihood of responding to induction therapy, while both ‘secondary-type’ AML muta- tions (those associated with AML arising after a prodromic myelodysplastic syndrome) and TP53 mutations are associ- ated with more resistant disease.3 The challenge facing the field is how to incorporate contrasting data from large stud- ies of heterogeneous patient populations that may lack suf- ficient data with regards to genetic variables and smaller studies with detailed clinical information and genetic anno- tation, but limited statistical power to identify independent genetic effects. The debate about ‘3+7’ chemotherapy ver- sus non-intensive therapy for older adults with AML contin- ues.6
How do the data provided by the German Austrian AML Study Group7 add to the discussion? Their study has several important strengths. First, only patients older than the age of 74 were included, enabling a distinct and focused evalu- ation of this under-studied population. Second, all patients received the same intensive induction chemotherapy on an AML Cooperative Group protocol,8 which compared stan- dard induction chemotherapy with thioguanine, daunoru- bicin, and cytarabine (TAD9) with a high-dose cytara- bine/mitoxantrone induction. Patients whose bone marrow samples showed residual AML on day 15 were to receive high-dose cytarabine/mitoxantrone. The doses of chemotherapy were attenuated in older adults. Third, the
authors performed targeted, next-generation sequencing of 64 genes known to be mutated in AML, paired with focused assessment of FLT3-ITD, NPM1, and CEBPA muta- tions by standard laboratory-validated methodologies. They looked at outcomes according to number and type of mutations along with other potentially relevant data such as patient’s age, cytogenetics, risk group by one of two clas- sifications systems, and randomized treatment assignment. More details about why these older adults received chemotherapy as opposed to other therapies would have been welcome. Were they particularly fit? Some actually had a performance status worse than 2, which is an adverse prognostic factor for response to chemotherapy.2 Obviously, no comparative group of patients treated con- temporaneously with less intensive chemotherapy can be provided.
The analysis highlights that some commonly employed prognostic factors in younger adult AML patients, including FLT3-ITD and NPM1, did not have the same relevance in the older patients. The European LeukemiaNet9 and Medical Research Council10 prognostic algorithms simply were not developed based on data from intensively treated patients in this age group. Given the distinct clinical and molecular features in this age group, one can begin to grasp why the ‘usual prognostic rules’ noted in younger patients may not apply. The findings in this cohort of 151 patients aged over 74 years old confirm those of published studies showing that there is a preponderance of gene mutations associated with myelodysplastic syndromes and clonal hematopoiesis of indeterminate potential in AML in older individuals.3,11,12 In a previous study, outcomes after 3+7- based chemotherapy were particularly poor in patients with histologically confirmed secondary AML or de novo AML harboring myelodysplastic syndrome-associated gene mutations.3 Although few patients in this study were older tha 74, it raised the idea that gene mutations suggestive of antecedent myelodysplastic syndromes (SRSF2, SF3B1, U2AF1, ZRSR2, BCOR, EZH2, ASXL1, STAG2) may high- light a subgroup of older patients with more chemoresis- tant disease. By contrast, older patients without such muta- tions had a much more favorable induction success rate and a 50% event-free survival.3
In the cohort reported by Prassek et al.,7 35% of the patients died during induction. This finding has important clinical implications, as older patients among a group of seemingly fit-for-chemotherapy patients may experience elevated treatment-related mortality due to a poor stem cell reserve, subtle organ dysfunction, and increased co-morbid disease, which may sometimes overwhelm the effect of disease biology. This finding offers important context for the interpretation of genetic results. In AML, the most prominent and reproducible associations between specific
haematologica | 2018; 103(11)